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Hippocampal alterations
in glutamatergic signaling
during amyloid progression
in AβPP/PS1 mice
Kevin N. Hascup1,2,3, Caleigh A. Findley1,2, Lindsey N. Sime1 & Erin R. Hascup1,2*
Our previous research demonstrated that soluble amyloid-β (Aβ)42, elicits presynaptic glutamate
release. We hypothesized that accumulation and deposition of Aβ altered glutamatergic
neurotransmission in a temporally and spatially dependent manner. To test this hypothesis, a
glutamate selective microelectrode array (MEA) was used to monitor dentate (DG), CA3, and CA1
hippocampal extracellular glutamate levels in 2–4, 6–8, and 18–20 month-old male AβPP/PS1 and agematched C57BL/6J control mice. Starting at 6 months of age, AβPP/PS1 basal glutamate levels are
elevated in all three hippocampal subregions that becomes more pronounced at the oldest age group.
Evoked glutamate release was elevated in all three age groups in the DG, but temporally delayed to
18–20 months in the CA3 of AβPP/PS1 mice. However, CA1 evoked glutamate release in AβPP/PS1
mice was elevated at 2–4 months of age and declined with age. Plaque deposition was anatomically
aligned (but temporally delayed) with elevated glutamate levels; whereby accumulation was first
observed in the CA1 and DG starting at 6–8 months that progressed throughout all hippocampal
subregions by 18–20 months of age. The temporal hippocampal glutamate changes observed in
this study may serve as a biomarker allowing for time point specific therapeutic interventions in
Alzheimer’s disease patients.
Abbreviations
mPD	1,3-Phenylenediamine dihydrochloride
AUC	Area under the curve
Aβ	β-Amyloid
AD	Alzheimer’s disease
ANOVA	Analysis of variance
AP	Anterior/posterior
AA	Ascorbic acid
BSA	Bovine serum albumin
DG	Dentate
DA	Dopamine
DV	Dorsal/ventral
FAST	Fast analytical sensing technology
GluCEST	Glutamate chemical exchange saturation transfer
ML	Medial/lateral
MEA	Microelectrode array
MCI	Mild cognitive impairment
MWM	Morris water maze
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NMDAR	N-methyl-d-aspartate receptors
PBS	Phosphate buffered saline
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder characterized by progressive anterograde
amnesia, cerebral atrophy, functional decline, and eventual death. Available pharmacotherapy options either
target cholinesterase inhibitors or partial antagonism of the N-methyl-D-aspartate receptors (NMDAR). However, these treatments have limited efficacy, are symptomatic, and are unable to decelerate disease p
 rogression1,2
possibly because they are administered at advanced AD stages when synapse loss is too pronounced. This lack of
disease modifying treatment is due to poor identification of effective biomarkers for early diagnosis. Accordingly,
intense efforts are ongoing to understand neurological changes associated with AD progression.
The hallmark proteinopathies associated with AD include extracellular β-amyloid (Aβ) plaques and intracellular hyperphosphorylated tau tangles that are both hypothesized to accumulate 20–30 years prior to onset
of mild cognitive impairment (MCI) and eventual AD3. In humans, the deposition of these proteins typically
follows a sequential pattern throughout the medial temporal lobe and thus is often used for post-mortem identification of disease s everity4. Deposition is often first observed in the entorhinal cortex and CA1 followed by
the dentate (DG) and C
 A35,6. The accumulation of these proteins either coincides with, or causes, alterations in
neurotransmitter dynamics7. For example, hippocampal hyperactivation during a memory encoding task was
observed a decade before cognitive decline in a cohort of individuals with the presenilin 1 (PS1) E280A mutation
that is associated with early onset A
 D8. A 3-year longitudinal study showed that elevated hippocampal activity
was present in plaque positive MCI patients who subsequently showed faster progression of cognitive decline
compared to MCI patients without plaque a ccumulation9. Finally, tau accumulation in cognitively normal older
adults was associated with hippocampal hyperactivity10,11. These studies support that aberrant hippocampal
neuronal activity precedes clinical AD diagnosis and suggests elevated glutamatergic signaling as the driving
force associated with disease p
 rogression12,13.
Glutamate is prevalent in neocortical and hippocampal pyramidal neurons and plays a role in synaptic plasticity, learning, and memory consolidation. Synaptic glutamate signaling is tightly regulated by clearance through
high-affinity excitatory amino acid transporters14. However, postmortem analysis shows that vesicular glutamate
transporter 1 boutons were elevated in pre-clinical AD cases15 while glutamate transporters were decreased in
AD patients16. Indicating mechanisms responsible for glutamatergic regulation are altered during different stages
of disease progression. A contributing factor to this dysregulation is the accumulation of soluble Aβ isoforms
that initiates synaptic dysfunction causing the eventual neurodegeneration17,18. For example, our laboratory
and others have demonstrated that Aβ42 elicits glutamate release19–21. Accordingly, mouse models of progressive
cerebral amyloidosis, such as the double transgenic mice expressing the amyloid precursor protein (Mo/HuAPP695swe) and Presenilin 1 (PS1-dE9) genes (AβPP/PS1), hippocampal glutamate is elevated at 12 months of
age22,23. Therefore, understanding changes to glutamatergic signaling at different stages of AD progression could
lead to the development of disease-stage specific therapeutics.
We hypothesized that accumulation and deposition of Aβ42 altered glutamatergic neurotransmission in a
temporally and anatomically spatial dependent manner. To probe this, in vivo hippocampal glutamate dynamics
were measured using an enzyme-based microelectrode array (MEA) coupled with constant potential amperometry in AβPP/PS1 mice. To determine the effects of disease progression on hippocampal glutamate, 2–4
(increased soluble Aβ42 but no plaque accumulation), 6–8 (initial plaque accumulation) and 18–20 (severe plaque
accumulation) month old AβPP/PS1 mice were examined. Age-matched C57BL/6J mice were used as genetic
background, normal aging controls. The results presented here indicate that AβPP/PS1 mice develop elevated
basal and stimulus-evoked glutamate release before plaque accumulation. These elevated glutamate levels change
with age and in a hippocampal subregion dependent manner that is independent from normal aging, which may
allow for the development for more targeted therapeutics on an individual level.

Results

Learning and memory retrieval. Cognitive performance was assessed using the Morris water maze
(MWM) learning and memory recall behavioral paradigm. No differences in learning were observed between
2–4 month and 6–8 month old AβPP/PS1 and age-matched C57BL/6J mice (Fig. 1A–F). At the 18–20 month
age range AβPP/PS1 were slower to learn the location of the hidden escape platform compared to age-matched
C57BL/6J mice as indicated by the cumulative distance from the platform (F1,24 = 5.111, P = 0.33) and the area
under the curve (AUC) of this parameter (t24 = 2.488, p = 0.02) as shown in Fig. 1G. This age group of AβPP/PS1
mice also spent less time searching the target quadrant for the escape platform ( F1,24 = 13.10, P = 0.0014) over
the five training sessions (t24 = 3.824, p = 0.0008 as shown in Fig. 1H. Additionally, AβPP/PS1 mice spent more
time navigating the periphery of the maze during the training sessions as indicated by percentage of time in
the thigmotaxic zone (F1,24 = 7.284, P = 0.01) and the AUC of this parameter (t24 = 3.016, p = 0.006) as shown in
Fig. 1I. Representative probe challenge path traces are shown in Fig. 1J–O. No differences in memory recall were
observed during the probe challenge between 2–4 and 6–8 month old AβPP/PS1 and C57BL/6J mice. However,
at 18–20 months of age, AβPP/PS1 had a further cumulative distance from the former location of the hidden
escape platform (Fig. 1P; t24 = 2.049, p = 0.05), searched less in the target quadrant (Fig. 1Q; t24 = 2.036, p = 0.05),
and more time searching the periphery of the pool (Fig. 1R; t24 = 2.145, p = 0.04) than age-matched C57BL/6J
mice.
In vivo DG glutamate dynamics. Representative glutamate release traces from the DG are presented in
Fig. 2A for C57BL/6J and AβPP/PS1 mice across all age groups studied. Basal glutamate (Fig. 2B) while decreased
at 2–4 months (t16 = 3.020, p = 0.008), is elevated at 6–8 months (t17 = 2.863, p = 0.01) and further increases by
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Figure 1.  MWM learning and memory recall. During the 5 day MWM training, each day consisted of 3 trials that
were averaged into a single data point for the cumulative distance (A,D,G), percentage of time in the target quadrant
(B,E,H) and percentage of time in the thigmotaxic zone (C,F,I) for each age group. Line graphs were analyzed using
a two-way ANOVA (Training Day × Genotype) with Sidak’s post-hoc analysis. The insets indicate the area under the
curve for the five training sessions that were analyzed using a two-tailed t-test. Representative track plots of the 60 s
probe challenge are shown for both genotypes at all ages tested (J–O). The blue and red dots indicate maze entrance
and ending location, respectively. The cumulative distance from the platform (P), percentage of time in the target
quadrant (Q) and percentage of time in the thigmotaxic zone (R). A two-tailed t-test was used to compare genotypes
within age groups. *p < 0.05, **p < 0.01, C57BL/6J n = 10–14, AβPP/PS1 n = 10–13.
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Figure 2.  DG glutamate dynamics. (A) Representative traces of glutamate release from 70 mM KCl stimulation (A). Columns
indicate treatment groups while rows indicate hippocampal subfields. The inset trace at the top of each panel depicts the
reproducibility of the glutamate signals. The single response shown beneath is a magnified view of the first inset signal (dashed
box) designed to give a clearer presentation of glutamate dynamics. Concentration and time axes are consistent in all panels
for comparative interpretation. (B) Basal glutamate was determined prior to local application of stimulus in each hippocampal
subfield. (C) The stimulus volume (nl, mean ± SEM) is shown beneath the abscissa. Stimulus volume was monitored and kept
consistent across treatment groups for direct comparison of glutamate release. (D) Release rate examines the rising portion of
the signal while clearance rate (E) quantifies the decay portion of the signal. A two-tailed t-test was used to compare genotypes
within age groups. *p < 0.05, **p < 0.01, ***p < 0.001, C57BL/6J n = 9–12, AβPP/PS1 n = 9–12.
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18–20 months of age ( t22 = 3.053, p = 0.006) in AβPP/PS1 mice compared to age-matched C57BL/6J. Additionally, C57BL/6J basal glutamate levels are decreased at 6–8 months of age, which contributes to the statistical
significance observed in AβPP/PS1 mice at this time point. The average glutamate release from local application
of 70 mM KCl was determined by subtracting the peak amplitude from the basal measure prior to stimulus ejection. The maximal amplitude of glutamate release (Fig. 2C) is elevated in AβPP/PS1 at 2–4 (t19 = 2.074, p = 0.05)
and 6–8 (t18 = 2.502, p = 0.02) months of age that continues to increase at the oldest age group studied (t21 = 4.308,
p = 0.0003) compared to age-matched C57BL/6J mice. The release rate of evoked glutamate is calculated by
determining the maximal amplitude of the signal (µM) and dividing by the change in time (s). No differences in
release rate (Fig. 2D) are observed between genotypes at 2–4 and 6–8 months of age, but AβPP/PS1 mice release
glutamate faster at 18–20 months of age ( t20 = 2.738, p = 0.01). Clearance of extracellular glutamate was calculated
by determining the amplitude change (µM) between 20 and 60 percent of the maximal signal and dividing by
the length of time (s) during this signal decay resulting in a clearance rate with units of µM/s. No differences
in glutamate clearance (Fig. 2E) are observed at 2–4 months of age, but is elevated in AβPP/PS1 mice at 6–8
(t18 = 2.041, p = 0.05), and 18–20 (t21 = 2.979, p = 0.007) months of age. In the DG, basal and stimulus-evoked
glutamate release increases with disease progression in AβPP/PS1.

In vivo CA3 glutamate dynamics. Figure 3A shows representative CA3 glutamate release traces for
C57BL/6J and AβPP/PS1 mice across all age groups. No differences in basal glutamate (Fig. 3B) are observed
at 2–4 months but becomes elevated in AβPP/PS1 mice at 6–8 months (t17 = 3.099, p = 0.007) and continues to
increase through 18–20 (t22 = 3.074, p = 0.006) months of age. Similar to DG recordings, CA3 basal glutamate
levels decrease in 6–8 month-old C57BL/6J mice and contributes to the statistically significant increase observed
in AβPP/PS1 mice at this time point. Maximal amplitude of glutamate release (Fig. 3C) is similar across genotypes at 2–4 and 6–8 months of age. CA3 glutamate release is not increased until 18–20 (t22 = 2.386, p = 0.03)
months of age compared to age-matched C57BL/6J mice. Similar to CA3 basal glutamate, no differences in
release rate (Fig. 3D) is observed at 2–4 months, but this becomes elevated at the 6–8 (t18 = 2.836, p = 0.01) and
18–20 (t22 = 1.691, p = 0.11) months of age in AβPP/PS1 mice. Only the 6–8 month old AβPP/PS1 mice have
faster clearance of evoked glutamate (Fig. 3E) compared to age-matched C57BL/6J mice ( t19 = 2.094, p = 0.04).
CA3 basal and evoked glutamate release become elevated as a result of disease progression; similar to the DG
but temporally delayed.
In vivo CA1 glutamate dynamics. Figure 4A depicts CA1 representative glutamate release traces for both
C57BL/6J and AβPP/PS1 mice across the three age groups tested. At 2–4 months of age no differences in CA1
basal glutamate are observed (Fig. 4B). AβPP/PS1 CA1 basal glutamate increases with disease progression and
is elevated at 6–8 (t20 = 2.618, p = 0.02) and 18–20 (t22 = 3.946, p = 0.001) months of age compared to age-matched
C57BL/6J mice. An opposite effect with disease progression is observed with CA1 stimulus-evoked glutamate
release (Fig. 4C). The younger age groups studied, 2–4 (t20 = 4.834, p = 0.0001) and 6–8 (t20 = 2.142, p = 0.04)
months of age have elevated glutamate release, but is similar to C57BL/6J mice at 18–20 months of age. AβPP/
PS1 CA1 release rate (Fig. 4D) tended to be elevated at the youngest age group only ( t20 = 1.800, p = 0.08). No
differences between genotypes are observed at the other age groups. The clearance of CA1 evoked glutamate
(Fig. 4E) is elevated in AβPP/PS1 mice early in disease progression at the 2–4 (t20 = 2.078, p = 0.05) and 6–8 (t20
1.612, p = 0.12) month time points, but no difference is observed at 18–20 months of age. CA1 glutamate dynamics are inverted with basal levels increasing and evoked-release decreasing with respect to disease progression.
Amyloid plaque staining. Amylo-Glo RTD plaque staining reagent was used to measure changes in amyloid plaque pathology throughout the hippocampus. Representative 10 × magnification images form the DG
and CA1/CA3 hippocampal subregions from all mice studied are shown in Fig. 5. Plaque pathology was not
observed in any C57BL/6J mice nor in the 2–4 month AβPP/PS1 age group as shown in Fig. 5A–H. Amyloid plaques were observed in the 6–8 (Fig. 5I,J) and 18–20 (Fig. 5K,L) month-old AβPP/PS1 mice. As AβPP/
PS1 mice aged, the number of amyloid plaques (Fig. 5E) increased in the DG (t20 = 4.415; P = 0.0003), CA3
(t19 = 3.851; P = 0.001) and CA1 (t18 = 5.307; P < 0.0001). Plaque size (Fig. 5F) was also increased with age in the
CA3 (t19 = 6.069; P < 0.0001) and CA1 (t18 = 2.425; P < 0.0260), but not the DG (t20 = 1.615; P = 0.12) of AβPP/
PS1 mice. Plaque accumulation was observed first in the DG and CA1 of 6–8 month old AβPP/PS1 mice that
progressed in quantity and area throughout the hippocampus by the 18–20 month time-point.

Discussion

One of the first preclinical symptoms associated with AD is attributed to hyperactive hippocampal neuronal
networks. Hippocampal hyperactivity is observed in Aβ positive MCI patients, which persists with disease
progression despite increasing rates of hippocampal atrophy and dementia scale ratings9. Elevated hippocampal
activity has also been reported in several mouse models of AD with progressive a myloidosis24–28. These changes in
neuronal networks are initially observed in mice before plaque d
 eposition29,30, supporting a role for soluble Aβ in
neuronal hyperactivity. Endogenous Aβ was shown to increase the release probability at excitatory synapses29,31,32
as well as stimulate synaptic glutamate r elease20,21. However, as Aβ42 accumulation leads to aggregation, the
neuronal proximity to the surrounding plaques determines their activity states. Neurons closest to the plaques
develop hyperactive phenotypes while those further from plaques are markedly silenced33. This may partially
be explained by the accumulation of soluble Aβ isoforms surrounding plaques that colocalize with postsynaptic
densities and cause synapse loss34. Furthermore, this would create a localized area of intense synaptic activity
that can propagate Aβ pathology35,36 and cause additional plaque deposition37. Thus a vicious cycle is created
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Figure 3.  CA3 glutamate dynamics. (A) Representative traces of 70 mM KCl evoked glutamate release in the
CA3 of 2–4 (left), 6–8 (middle), and 18–20 (right) month old C57BL/6J (top row) and AβPP/PS1 (bottom row)
mice. The reproducibility of the glutamate signal (inset) and magnified first signal (dashed box) is shown in
each panel. Basal glutamate, stimulus-evoked glutamate release average amplitude, glutamate release rate, and
clearance rate (B–E) were calculated as previously described. A two-tailed t-test was used to compare genotypes
within age groups. *p < 0.05, **p < 0.01, C57BL/6J n = 8–12, AβPP/PS1 n = 8–12.
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Figure 4.  CA1 glutamate dynamics. (A) Stimulus-evoked glutamate release representative traces from the
CA1 of C57BL/6J and AβPP/PS1 mice (rows) across all ages tested (columns). Within each panel the signal
reproducibility is shown as an inset with the corresponding first signal (dashed box) magnified. Basal glutamate,
stimulus-evoked glutamate release average amplitude, glutamate release rate, and clearance rate (B–E) were
calculated as previously described. A two-tailed t-test was used to compare genotypes within age groups.
*p < 0.05, **p < 0.01, ***p < 0.001, C57BL/6J n = 7–13, AβPP/PS1 n = 9–12.
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Figure 5.  Aβ plaque staining. Representative hippocampal images at 10 × magnification of amyloid plaques
staining in C57BL/6J (A–F) and AβPP/PS1 (G–L) mice at 2–4, 6–8, and 18–20 months of age. Plaques were
only observed in 6–8 month- (I,J; purple arrows) and 18–20 month-old (K,L; teal arrows and brackets) AβPP/
PS1 mice. Scale bar represents 100 µm. Average number of plaques (M) and the average plaque size (N) in each
hippocampal subregion. A two-tailed t-test was used to compare ages within the AβPP/PS1 mice. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001; 6–8 months n = 9–10; 18–20 months n = 11–12 AβPP/PS1 mice.
whereby intensified glutamatergic activity and amyloid accumulation extend throughout cortical areas, contribute
to seizure a ctivity38, and cascade into the degenerative processes observed in AD39.
In the present study, learning and memory recall deficits in AβPP/PS1 mice were only observed at the oldest
age group studied. Discordant results exist in the literature regarding when AβPP/PS1 mice begin to experience
MWM cognitive deficits. Differences in cognition can begin by 6 months of a ge40 with others reporting first
appearance at 10 months that progresses with age41 that are in line with the present study and our prior work22.
Increased thigmotaxic behavior was also observed in the oldest AβPP/PS1 age group studied, similar to previous
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reports in this transgenic AD m
 odel42. When first navigating the MWM, mice tend to remain close to the wall
until they learn to search the middle of the pool for an escape route. While learning the MWM, the thigmotaxic
behavior in 18–20 month-old AβPP/PS1 subsided slower and was more prevalent during the probe challenge
compared to age-matched C57BL/6J mice. This may be indicative of sensorimotor impairments and anxiety that
affected learning and memory in AD mice at 18–20 months of age.
AβPP/PS1 mice progressively accumulate soluble Aβ42 starting as early as 3 months of age43. This accumulation eventually determines amyloid burden that becomes visible by 6 months of age and increases throughout the
lifespan of these transgenic m
 ice44,45. Likewise, the present study indicated no plaque deposition at 3 months of
age, but by 6 months of age, plaque accumulation was most prominent in the CA1 followed by the DG with little
to none observed in the CA3. As AβPP/PS1 mice reach 18 months of age, the magnitude of plaque deposition
increases throughout the hippocampus, and this subregion distribution pattern continues including observable
plaque pathology in the CA3.
Because plaque burden is a result of Aβ42 accumulation in AβPP/PS1 m
 ice44, the subregion distribution pattern of plaque deposition is indicative of soluble Aβ42 concentration. This disease stage dependent progression
of amyloid accumulation and deposition explains the basal and evoked glutamate release data reported in this
manuscript. Elevated evoked glutamate release was prominent in the CA1 and DG at 2–4 and 6–8 months of
age, but this was not observed until 18–20 months of age in the CA3. Elevated basal glutamate follows a similar
hippocampal subregion distribution pattern that becomes more pronounced with age. However, this is temporally
delayed to 6–8 months which may indicate amyloid accumulation first sensitizes neurons for increased release,
then progresses to consistently elevated circulating levels of glutamate. The CA1 was the only subregion where
evoked glutamate release declines with age despite increasing plaque deposition. A reduction of CA1 dendritic
architecture was linked to enhanced cellular excitability at an age when plaque deposition was p
 resent26. However, as Aβ42 accumulation progresses, a threshold may be passed where neurons become hypoactive or synapse
loss is too p
 ronounced30 that diminishes glutamate release. Further studies are required to understand the how
hippocampal soluble Aβ42 levels contribute to changes in glutamatergic neurotransmission.
The pattern of amyloid deposition presented here is similar to the Braak neuropathological staging of hippocampal amyloid progression in AD5,6. This staging also coincides with CA1 neuronal loss occurring before
other hippocampal s ubregions46,47. It is known that CA1 neurons are more vulnerable to global cerebral i schemia48
and degenerate faster in epileptic patients49. The underlying cause of selective CA1 neuronal degeneration is
a result of glutamate-mediated excitotoxic mechanisms involving excessive calcium influx through NMDAR
activation, mitochondrial dysfunction, and reactive oxygen species. These events culminate in necrotic cell loss
that releases more glutamate into the extracellular space thus propagating damage to surrounding neurons.
This process supports our discordant CA1 glutamate observations with increasing basal but decreasing evoked
glutamate release with age in AβPP/PS1 mice.
This research builds upon a growing body of literature indicating temporally altered hippocampal glutamatergic signaling during the progression of AD pathology. Our previous studies support hippocampal glutamate levels
are still elevated at 12 months of age in male AβPP/PS1 mice22,23. Others have shown this is not a sex specific
characteristic since female AβPP/PS1 mice have elevated CA1 dialysate glutamate levels at 7 months of age that
also decline by 17 months of a ge41. Noninvasive techniques such as glutamate chemical exchange saturation
transfer GluCEST also indicate a decrease in hippocampal glutamate in 18–20 months old AβPP/PS1 mice50.
Interestingly these observations are not specific for progression of amyloid pathology. Electrochemical studies in
the 5–8 month old tau mouse model of AD, P301L, develop elevated hippocampal g lutamate51,52. A separate tau
mouse model, P301S, also has elevated hippocampal glutamate at 3 months old, that declines at 18–20 months
of age53,54 as measured by GluCEST techniques. While the amyloid and tau pathology are likely acting through
different mechanisms to elicit glutamate release, these studies show a concomitant change in vesicular glutamate
transporter 1 that corresponds to the elevated glutamate levels regardless of AD pathology. When considered
with the present research, these studies support temporal changes in hippocampal glutamate during AD progression with elevated levels early in pathology that decline in later disease stages. Understanding these types of
regional differences may help to refine severity and progression of AD and tailor appropriate treatment options.
In early AD stages, before overt atrophy, overactivation of the NMDAR is hypothesized to impede detection
of physiological signals leading to the cognitive impairment observed in AD39,55. Accordingly, meta-analysis
of memantine treatment, a partial NMDAR antagonist, ameliorates cognitive and functional performance in
mild-to-moderate AD patients when administered as monotherapy or in combination with anticholinesterase inhibitors56. This treatment only delays cognitive decline and does not have disease modifying b
 enefits57.
Since memantine modulates glutamate signaling rather than attenuating the glutamatergic tone, the persistently
elevated glutamate levels during AD progression may induce excitotoxic effects that accounts for the neuronal,
cognitive, and functional loss. As such, drugs that attenuate glutamate release or enhance clearance may provide
long-term therapeutic benefits if initiated before signs of cognitive impairment.

Conclusion

These data support a growing body of literature indicating hyperactive hippocampal glutamate signaling contributes to AD pathogenesis. The temporal hippocampal glutamate changes observed in this study may serve as
a biomarker allowing for time point specific therapeutic interventions that can be tailored for maximal efficacy.
Simultaneously monitoring changes in hippocampal glutamate with plaque and tangle pathology may further
refine stages of AD progression.
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Methods

Animals. Male C57BL/6J (RRID:IMSR_JAX:000,664) and AβPP/PS1 (RRID:MMRRC_034832-JAX) mice
were obtained from Jackson Laboratory (Bar Harbor, ME). Protocols for animal use were approved by the Laboratory Animal Care and Use Committee at Southern Illinois University School of Medicine, which is accredited
by the Association for Assessment and Accreditation of Laboratory Animal Care. Mice were group housed on
a 12:12 h light: dark cycle, and food and water were available ad libitum. Mice arrived to our animal facility
at ~ 8 weeks of age and acclimated for 1 week before randomly assigned into one of three age groups: 2–4, 6–8, or
18–20 months for study analysis. Mice were euthanized with an overdose of isoflurane followed by rapid decapitation. Genotypes were confirmed by collecting a 5 mm tail snip for analysis by TransnetYX, Inc (Cordova, TN).
Chemicals. l-Glutamate oxidase (EC 1.4.3.11) was obtained from Cosmo Bio Co. (Carlsbad, CA) and diluted
in distilled, deionized water to make a 1 U/µl stock solution for storage at 4 °C. Sodium phosphate monobasic
monohydrate, sodium phosphate dibasic anhydrous, 1,3 phenylenediamine dihydrochloride (mPD), sodium
chloride, calcium chloride dihydrate, and H2O2 (30% in water) were obtained from Thermo Fisher Scientific
(Waltham, MA). l-Glutamic acid sodium salt, bovine serum albumin (BSA), glutaraldehyde, KCl, dopamine
hydrochloride (DA), and l-ascorbic acid (AA) were obtained from Sigma-Aldrich Co. (St. Louis, MO).
Morris water maze training and probe challenge. The MWM was used to assess spatial learning and
memory recall. Mice were trained to utilize visual cues placed around the room to repeatedly swim to a static,
hidden escape platform (submerged 1 cm below the opaque water surface) regardless of starting quadrant23,58.
The MWM paradigm consisted of 5 consecutive training days with three, 90 s trials/day and a minimum intertrial-interval of 20 min. Starting quadrant was randomized for each trial. After two days without testing, the
escape platform was removed and all mice entered the pool of water from the same starting position for a single,
60 s probe challenge to test long-term memory recall. The ANY-maze video tracking system (Stoelting Co.,
Wood Dale, IL; RRID:SCR_014289) was used to record mouse navigation during the training and probe challenge. The three trials for each training day were averaged for each mouse.
Enzyme‑based microelectrode arrays. Enzyme-based MEAs with platinum (Pt) recording surfaces

(Fig. 6A) were fabricated, assembled, coated (Fig. 6B), and calibrated for in vivo mouse glutamate measurements as previously d
 escribed59–61. One microliter of glutamate oxidase stock solution (1 U/µl) was added to
9 µl of a 1.0% BSA and 0.125% glutaraldehyde w/v solution and applied dropwise to a Pt recording surface. This
preparation aides in enzyme adhesion to the Pt recording surface for enzymatic degradation of glutamate to
α-ketoglutarate and H
 2O2, the electroactive reporter molecule. The other Pt recording site (self-referencing or
sentinel site) was coated with the BSA/glutaraldehyde solution, which is unable to enzymatically generate H2O2
from l-glutamate. A potential of + 0.7 V vs a Ag/AgCl reference electrode was applied to the Pt recording surfaces resulting in oxidation of H2O2. While + 0.7 V is capable of oxidizing potential interferants, such as AA and
DA, lower potentials are unable to adequately oxidize H2O2 and subsequently detect glutamate62. The current
generated from the two electron transfer was amplified and digitized by the Fast Analytical Sensing Technology
(FAST) 16mkIII (Quanteon, LLC; Nicholasville, KY) electrochemistry instrument.

mPD electropolymerization. After enzyme coating, Pt recording surfaces were electroplated with 5 mM
mPD in 0.05 M phosphate buffered saline (PBS) to block potential interferants oxidizable at + 0.7 V (Fig. 6B).
FAST electroplating software applied a triangular wave potential with an offset of − 0.5 V, peak-to-peak amplitude of 0.25 V, at a frequency of 0.05 Hz, for 20 min. This created a size exclusion layer that restricts the passage
of AA, DA, uric acid and 3,4-dihydroxyphenylacetic acid to the Pt recording s urface63.
Calibration. MEAs were calibrated according to previously published protocols22,23. MEAs were placed in

a stirred solution of 40.0 mL of 0.05 M PBS held constant at 37 °C using a recirculating water bath (Stryker
Corp., Kalamazoo, MI). Using a glass Ag/AgCl reference electrode (Bioanalytical Systems, Inc., West Lafayette,
IN), MEAs were calibrated with final beaker concentrations of 250 µM AA, 10, 20, 30, and 40 µM l-glutamate,
2 µM DA, and 8.8 µM H2O2 to create a standard curve for the conversion of current to glutamate concentration.
Seventy-one MEAs were calibrated and the average ± standard error of the mean (SEM) for glutamate sensitivity
was 8.9 ± 0.1 pA/μM (R2 = 0.996 ± 0.001), selectivity ratio of 442 ± 63 to 1, and limit of detection of 0.23 ± 0.03 μM
based on a signal-to-noise ratio of 3.

Microelectrode array/micropipette assembly. Glass micropipettes (1.0 mm outer diameter, 0.58 mm
internal diameter; World Precision Instruments, Inc., Sarasota, FL) were pulled using a vertical micropipette
puller (Sutter Instrument Co., Novato, CA). The tip was “bumped” to create an internal diameter of 12–15 µm.
The micropipette tip was positioned between the pair of recording sites and mounted 100 µm above the MEA
surface (Fig 6D). The micropipettes were filled with sterile filtered (0.20 µm) 70 mM KCl (70 mM KCl, 79 mM
NaCl and 2.5 mM C
 aCl2, pH 7.4). Fluid was pressure-ejected from the glass micropipette using a Picospritzer III
(Parker-Hannafin, Cleveland, OH), with pressure (5–15 psi) adjusted to consistently deliver volumes between
100–200 nl over 1–2 s intervals. Ejection volumes were monitored with a stereomicroscope (Luxo Corp., Elmsford, NY) fitted with a calibrated reticule20.
Reference electrode. A Ag/AgCl reference wire was prepared as previously d escribed22,23. The Teflon from

both ends of a silver wire (200 μm bare, 275 μm coated; A-M Systems, Carlsberg, WA) was removed and one end
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Figure 6.  Images, enzyme coating, and implantation of MEAs for selective glutamate recordings. MEA images
are shown in (A). The R2 MEA consists of a printed circuit board (yellow, top) with soldered gold plated pins
for connection to the FAST system and a wire bonded working electrode (bottom, tapered tip) that measures
4 cm in length. A magnified view of the working electrode with two independent platinum recording sites
(50 × 100 microns) is shown on the right. A coating schematic illustration for selective glutamate recordings is
shown (B). Site 1 is coated with glutamate oxidase, BSA, and glutaraldehyde (green) while Site 2 is coated with
the inactive protein matrix consisting of BSA and glutaraldehyde (blue). Glutamate is enzymatically cleaved by
glutamate oxidase to form the electroactive reporter molecule H
 2O2, but not on Site 2 coated with the inactive
protein matrix. MEA selectivity for glutamate is improved by electropolymerizing mPD onto both recording
surfaces, which forms a size exclusion layer that blocks ascorbic acid, 3,4-dihydroxyphenylacetic acid (DOPAC),
and DA that are electrochemically active at our working potential. Mice are isoflurane anesthetized and placed
in a stereotaxic frame (C). The MEA (green)/micropipette assembly (blue) is fixed to probe holder (C) attached
to the stereotaxic arm for positioning into the different hippocampal subregions (D). Images (C) and (D) were
prepared using BioRender.
soldered to a gold-plated connector (Newark element14 Chicago, IL). The other stripped end was placed (cathode) into a 1 M HCl bath saturated with NaCl that also contained a stainless steel counter wire (anode). Passing
a + 9 V DC to the cathode versus the anode for 15 min deposits Ag/Cl onto the stripped wire.

In vivo anesthetized recordings. One week after MWM, mice were anesthetized using 1.5–2.0% iso-

flurane (Abbott Lab, North Chicago, IL) in a calibrated vaporizer (Vaporizer Sales & Service, Inc., Rockmart,
GA)63. The mouse was placed in a stereotaxic frame fitted with an anesthesia mask (Fig. 6C; David Kopf Instru-
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ments, Tujunga, CA). Body temperature was maintained at 37 °C with a water pad (Braintree Scientific Inc.,
Braintree, MA) connected to a recirculating water bath. A craniotomy was performed to access the DG (AP:
− 2.0, ML: ± 1.0, DV: − 2.2 mm), CA3 (AP: − 2.0, ML: ± 2.0, DV: − 2.2 mm), and CA1 (AP: − 2.0, ML: ± 1.0, DV:
− 1.7 mm) from B
 regma64. Recordings were conducted using a two electrode system whereby a Ag/AgCl reference wire was positioned beneath the skull and rostral to the craniotomy and a working electrode was positioned
in one of the hippocampal subregions (Fig. 6D). Constant voltage amperometry (4 Hz) was performed with a
potential of + 0.7 V vs the Ag/AgCl reference electrode applied by the FAST16mkIII. MEAs reached a stable
baseline for 60 min before a 10 s basal glutamate determination and pressure ejection studies commenced. Once
five reproducible signals were evoked, the MEA was repositioned into a new hippocampal subfield, which was
randomized for each mouse. The FAST software saved amperometric data, time, and pressure ejection events.
Calibration data, in conjunction with a MATLAB (MathWorks, Natick, MA; RRID:SCR_001622) graphic user
interface program was used to calculate basal, stimulus-evoked, and clearance of extracellular glutamate. The
evoked glutamate signals in each hippocampal subfield were averaged into a representative signal for comparison.

Amyloid plaque staining and semi‑quantification. Sections were prepared, stained and quantified as

previously described22,23. After electrochemistry, brains were removed and post-fixed in 4% paraformaldehyde
for 48 h and then transferred into 30% sucrose in 0.1 M phosphate buffer for at least 24 h prior to sectioning.
Twenty µm coronal sections through the hippocampus were obtained using a cryostat (Model HM525 NX,
Thermo Fisher Scientific). Mounted sections were treated with 10% H2O2 in 20% methanol for 10 min, transferred to 70% ethanol solution for 5 min, and then washed with PBS for 2 min. Sections were incubated for
10 min in Amylo-Glo RTD (1:100; Biosensis, Temecula, CA), submerged in physiological saline for 5 min, and
rinsed three times in separate PBS solutions for 2 min. Sections were coverslipped using Fluoromount-G (SouthernBiotech; Birmingham, AL). Staining intensity was controlled for by imaging all sections the next day. Images
were captured with an Olympus 1 × 71 microscope equipped with an Olympus-DP73 video camera system, and
a Dell Optiplex 7020 computer. National Institutes of Health Image J Software (v. 1.48; RRID:SCR_003070) was
used to measure relative staining density by using a 0–256 Gy scale. Staining density was obtained when background staining was subtracted from mean staining intensities on every sixth section through the hippocampus.
Individual templates for the DG, CA3, and CA1 were created and used on all brains similarly. Measurements
were performed blinded, and approximately four sections were averaged to obtain one value per subject. Amyloid plaques were identified by a dense spherical core of intense staining that were often surrounded by a less
compact spherical halo.

Data analysis. Prism (GraphPad Prism 8 Software, Inc., La Jolla, CA; RRID:SCR_002798) software was
used for statistical analyses. For glutamate measurements and amyloid plaque staining, hippocampal subregions
were examined independently. For statistical analysis, genotypes were compared within age groups and all tests
are listed in the figure legends. Outliers were identified with a single Grubbs’ test (alpha = 0.05) per group. Data
are represented as mean ± SEM and statistical significance was defined as p < 0.05.

Data availability

Data is available upon reasonable request.
Received: 2 April 2020; Accepted: 18 August 2020
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